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Background: Overexpression of SLMAP gene has been associated with diabetes and endothelial dysfunction of
macro- and micro-blood vessels. In this study our primary objective is to explore the role of SLMAP gene polymorphisms
in the susceptibility of type 2 diabetes (T2DM) with or without diabetic retinopathy (DR) in the Qatari population.
Methods: A total of 342 Qatari subjects (non-diabetic controls and T2DM patients with or without DR) were
genotyped for SLMAP gene polymorphisms (rs17058639 C > T; rs1043045 C > T and rs1057719 A > G) using Taqman
SNP genotyping assay.
Results: SLMAP rs17058639 C > T polymorphism was associated with the presence of DR among Qataris with T2DM.
One-way ANOVA and multiple logistic regression analysis showed SLMAP SNP rs17058639 C > T as an independent risk
factor for DR development. SLMAP rs17058639 C > T polymorphism also had a predictive role for the severity of DR.
Haplotype Crs17058639Trs1043045Ars1057719 was associated with the increased risk for DR among Qataris with T2DM.
Conclusions: The data suggests the potential role of SLMAP SNPs as a risk factor for the susceptibility of DR
among T2DM patients in the Qatari population.
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Currently, 387 million people worldwide have diabetes,
which is approximately 8.3% of the total adult popula-
tion and in 2014 diabetes contributed to 4.9 million
deaths [1]. Three of the world’s top 10 countries with
the highest prevalence (%) of diabetes are Saudi Arabia,
Kuwait, and Qatar [2]. In Qatar, the prevalence of
diabetes is increasing (16.28% vs 8.5% global) with the
total diabetic population expected to increase by 130%
by 2030 [1-3].
Consistently high blood glucose levels associated with
type 2 diabetes (T2DM) can lead to serious disabling
and life-threatening complications including retinop-
athy. The mechanism of hyperglycemia induced retinal* Correspondence: hod2005@qatar-med.cornell.edu
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unless otherwise stated.microvascular damage is not clear, however, multiple
interconnected pathways including polyol pathway,
activation of protein kinase C (PKC), increased vascular
endothelial growth factor (VEGF) and insulin-like growth
factor-1 (IGF-1), accelerated formation of advanced glyca-
tion endproducts (AGEs), oxidative stress, activation of
the renin-angiotensin-aldosterone system (RAAS), and
subclinical inflammation and capillary occlusion have
been proposed [4]. Diabetes is responsible for approxi-
mately 12% of all causes of blindness [5], and diabetic ret-
inopathy (DR) prevalence among diabetes patients has
been estimated 34.6% [6-9]. About 1/3 of patients with
T2DM develop signs of DR, and a 1/3 of these are afflicted
with vision-threatening retinopathy [6], although there
is a disparity in the risk of T2DM/ DR between different
ethnic groups [10]. The Qatari population has one of
the highest prevalence rates for diabetes, but has not
been explored genetically.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ation of diabetes plays a significant role on the impact of
development and progression of DR; however, other factors
including genetic variations also contribute to the develop-
ment of T2DM and associated DR as evident from previous
literature [10-12]. Recently Rodriguez-Flores et al. [13],
assessed 100 Qataris by exome sequencing and reported
many unique variations as well as a higher frequency of
variants in comparison with 1000 Genomes populations,
suggesting that the Qatari population may have unique
genetic associations for disease risk. Qatari individuals can
be subdivided into three clearly definable subpopulations:
Q1-Bedouin, Q2-Persian- South Asian, and Q3-African
ancestry [14,15]. Each of these subpopulations has been
shown to have a high degree of consanguinity [13,16].
With this background, the focus of this study was to
assess the genetic variations of SLMAP (sarcolemma
associated protein; OMIM ID: 602701) gene in the
Qatari population with and without T2DM. SLMAP is a
protein-coding gene associated with frozen shoulder,
Becker muscular dystrophy, Brugada syndrome and dia-
betes (www.genecards.org) [17-19]. SLMAP is localized
to chromosome 3p21.2-p14.3 in the human genome, a
region that is also enriched in genes linked to T2DM
[20-22]. SLMAP has 26 exons that encode several iso-
forms with 21 splice variants via alternative splicing
[22,23]. Although the functional involvement of SLMAP
in diabetic pathophysiology is still under investigation,
SLMAP expression levels have been linked to vascular
dysfunction in diabetes [18], and studies using diabetic
db/db and diabetic Tally Ho mice suggest that deregula-
tion of SLMAP expression may play an important role
in T2DM [18,24].
The role of SLMAP gene polymorphisms in susceptibility
of diabetes (with or without retinopathy) has not been ex-
plored. In this article, we aimed to assess the contribution
of SLMAP gene polymorphisms to the susceptibility of
T2DM with or without DR and their association with clin-
ical phenotypes in the Qatari population. Three SLMAP
SNPs [SLMAP rs17058639 C >T; SLMAP rs1043045 C >T
and SLMAP rs1057719 A >G]; representing the major hap-
logroup of the gene (Figure 1) and predicted to have func-
tional roles: either by abolishing protein domain through
splicing (rs17058639 C >T) or due to binding of micro
RNA in an allele specific manner (rs1043045 C >T/
rs1057719 A >G); were evaluated in this study.
Materials and methods
Study subjects
A total of 342 Qatari subjects were recruited for this
study from the clinics of Hamad Medical Corporation
(HMC) and HMC satellite clinics in Doha, Qatar. Sub-
jects were individually interviewed with approved ques-
tionnaire for ethnicity, family history of disease andother demographic/clinical details. Subjects with incom-
plete clinical information/diagnosis were excluded. The
parameters assessed included age, gender, fasting glucose
levels, body-mass index (BMI), creatinine levels, glycated
hemoglobin (HbA1C) levels, high density lipid (HDL)/
low density lipid (LDL) concentration, triglyceride level,
blood urea nitrogen level (BUN), presence/absence of
DR, DR subtypes, family history of disease, usage of oral
hypoglycemic or insulin, and occurrence of gestational
diabetes. According to the clinical diagnosis subjects
were divided into three groups: Non-diabetic controls
(NDC), T2DM patients without retinopathy (DNR) and
diabetic patients with retinopathy (DR). The diagnosis of
DR patients was done by standard clinical procedures
and retinal phenotypes and verified by two independent
ophthalmologists at, clinics of Hamad Medical Corpor-
ation (HMC), Doha, Qatar and Weill Cornell Medical
College in New York City, USA. In this study the total
number of subjects in NDC, DNR and DR groups was
104, 160 and 78 respectively.
Among the NDC group, ~50% of subjects had BMI >30;
however their fasting glucose, triglycerides, and other
metabolic markers were normal. This type of subjects usu-
ally referred as the “metabolically healthy obese” (MHO)
and are assumed to be at no higher risk for T2DM or car-
diovascular disease (CVD) than their metabolically healthy
lean counterparts [25]. A fraction of subjects (N = 36) se-
lected for present study was previously assessed for exome
sequencing by Rodriguez-Flores et al. [13]. All of the sub-
jects were third generation Qataris and whose ancestors
were Qatari citizens by birth. Recent immigrants or resi-
dents of Qatar who traced their recent ancestry to other
geographic regions were excluded. Each individual was
genotyped for a panel of 48 SNPs through TaqMan (Life
Technologies, Carlsbad, CA) to determine Q1, Q2, or Q3
ancestry in a Qatari individual [14]. Approximately 95%
individuals in the present study had Q1 ancestry. Human
subjects were recruited and written informed consents
were obtained at HMC, Doha, Qatar. The study protocol
was approved by the joint Hamad-Weill Cornell-Qatar
Medical Research Center & Research Committee and
the Institutional Review Board of Weill Cornell Medical
College in Qatar (WCMC-Q).
Genotyping
DNA was isolated from blood samples using QIAamp
DNA blood kit following the manufacturer’s instructions
(Qiagen, Valencia, CA, USA). The qualities of isolated
genomic DNAs were checked using Nanodrop Analyzer
(ND-1000) spectrophotometer (Nano Drop Technologies,
Inc., Wilmington, DE, USA). The ratio of absorbance
of DNA at 260 and 280 nm was 1.7–1.9. Isolated DNA
was stored at −20°C. All SNP genotyping were per-
formed using the Taqman SNP genotyping assay (Applied
Figure 1 Haplotype organisation of SLMAP gene and selected SNPs. Haplotype organisation of SLMAP gene in the “CEU + TSI” population;
The haplotype block pattern was constructed using the Haploview v4.1 using data from the HapMap project; Haploblocks were defined by four
gamete rule; Measures of linkage disequilibrium (r2) among selected (three) SLMAP SNPs is shown by encircling the values in haploblock 3
(rs17058639: rs1057719 = 0.98; rs17058639: rs1043045 = 0.97; rs1057719: rs1043045 = 0.98).
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carried out according to the manufacturer’s protocol. The
probe fluorescence signal detection was performed using
the ABI step-one fast Real-Time PCR System.
Statistical analysis
Sample size calculations were done through Quanto ver.
1.2.4 software [26]. Diabetic prevalence in Qatar was taken
as 16% in the total population; threshold level for sig-
nificance was set at 0.05 and MAF was assumed ~30%
(Additional file 1: Table S1; minimum global MAF
was >30%). Upon putting these parameters to check
a relative risk of 2.0 with Quanto ver. 1.2.4 software,
we concluded that a study of 76 cases and 76 controls had
80% power in a log additive model to detect a SNP with
the disease-causing variant.
Data were analyzed using SPSS 15.0 (Chicago, IL,
USA). The χ2 goodness-of-fit test was used to determine
differences in genotype and allele frequencies and devi-
ation from Hardy–Weinberg equilibrium. Descriptive
statistics of patients (T2DM with or without DR) and
controls are presented as mean and standard deviation
for continuous measures, or as frequency and percent-
age for categorical measures. The significance level for
all statistical tests was set at P < 0.05. P-values were cor-
rected (Pcorr) for multiple comparisons (Bonferroni cor-
rection) in case of further subgrouping or stratification.
An independent t-test was applied to compare means of
continuous variables; however, chi-square P-value was
estimated for categorical variables. Logistic regression
was used to calculate the odds ratio for various predic-
tors, adjusting for the confounding effects of age and
gender. The homozygous genotype for the low risk pre-
dicted allele in the control group (or DNR group for DR
group) was used as the reference in calculating oddsratios (OR) for T2DM groups “with or without” DR and
95% confidence intervals (95% CI). Ptrend analysis was
performed to detect a disease severity dependent risk
trend with genotypes. Analysis for the recessive model
was also performed, where homozygous and heterozy-
gous low risk (predicted) alleles were clubbed and taken
as reference.
To detect association of genetic polymorphism with
continuous clinical variables, one-way ANOVA analysis
was performed. Mean values of continuous variables were
compared among SLMAP genotypes and P value was esti-
mated. To predict the cumulative risk variables in over-
all study multiple regression analysis was performed. “t
statistics” in multiple regression analysis was used to
identify significant predictors of the disease in the study.
Significance was determined when the “t values” was
well below −2 or above +2 and P value was <0.05.
Haplotypes were constructed through SNP-Analyzer
2.0 [27]. D′ and r2 values were calculated as measure
indices of linkage disequilibrium (LD). LD plot was
constructed and r2 values (for Hapmap populations)
were obtained through “Haploview” software. Further-
more, disease risk due to haplotypes was calculated by
logistic regression analysis through SPSS 15.0.
Results
SNP selection and function prediction
The SLMAP gene spans approximately 173.72 kb
(57755450 bp to 57929168 bp) has a total of 3108
SNPs; none have previously been explored in T2DM or
associated complications. We selected functional polymor-
phisms of SLMAP, through two SNP function predictor
and prioritization software “SNP-info” and “Fast SNP”
[28,29], having a minor allele frequency (MAF) >20% to get
appropriate power of study. In the present study, after
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rs17058639 C >T, rs1043045 C >T and rs1057719 A >G.
SLMAP rs17058639 C > T is a synonymous coding
region polymorphism (FS score 0.910) predicted to be
involved in splicing of SLMAP gene; rs1043045 C > T
and rs1057719 A > G are located at 3`UTR region and
predicted to have allele specific binding with hsa-miR-
936 and hsa-miR-197 respectively (both have FS score
0.101) (Additional file 1: Table S1). Selected all three
SNPs were located in the 3rd haplogroup of SLMAP
gene (Figure 1). This haplogroup is the major hap-
logroup of SLMAP gene which covers 110 kb region of
total 173.72 kb gene.
Clinical and demographic characteristics of study subjects
T2DM subjects with or without retinopathy had higher
BMI and increased level of glucose, glycated hemoglobin
A1c, HDL, triglycerides compared to NDC. There were
no differences in these parameters among T2DM pa-
tients with or without retinopathy (Table 1). DR patients







Mean Age (Yrs ± SD) 46.81 ± 10.32 55.64 ± 10.2
Gender: Males 44 (42.3%) 58 (36.3%)
Gender: Females 60 (57.7%) 102 (63.8%)
Mean Glucose levels (mmole/lit) ± SD 5.36 ± 0.97 10.55 ± 6.68
BMI (mean) 30.41 ± 6.70 34.08 ± 6.99
Creatinine level (micromole/lit) ± SD 72.44 ± 36.81 69.30 ± 28.5
Glycated hemoglobin (HbA1c) mean% ± SD
(mmol/mol)
5.63 ± 0.42 (38) 8.24 ± 1.72 (
Total Cholesterol (mmol/lit) mean ± SD 5.07 ± 0.87 4.88 ± 0.99
HDL (mmol/lit) mean ± SD 1.40 ± 0.34 1.22 ± 0.34
LDL (mmol/lit) mean ± SD 3.11 ± 0.77 2.95 ± 0.94
HDL/LDL ratio (mean ± SD) 0.48 ± 0.18 0.45 ± 0.19
Triglycerides (mmol/lit) mean ± SD 1.24 ± 0.56 1.77 ± 1.23
Blood Urea Nitrogen (mmol/lit) mean ± SD 5.14 ± 2.42 5.24 ± 2.54
DR subtypes: No DR: BDR/NPDR: PDR:DME 104:0:0:0 160:0:0:0
Presence of 1° Family history of diabetes 4/109 (3.67%) 45/160 (28.4
Usage of Hypoglycemics 0 136 (85.0%)
Usage of Insulin 0 66 (41.3%)
Fasting plasma glucose ≥7 mM 60 (37.5%)
Gestational diabetes in females (n;%) 7 (11.7%)/60 48 (47.06%)
Diabetes occurrence after pregnancy 0/65 28 (27.5%)/1
NDC = Non diabetic controls; T2DM = Type 2 Diabetes mellitus; DNR = Diabetic non-
retinopathy; PDR = Proliferative diabetic retinopathy; BDR = Background diabetic ret
values shown in bold.creatinine, HDL/LDL ratio, as well as increased insulin
usage compared to DNR. Also, T2DM patients with or
without retinopathy had a higher prevalence of a family
history of diabetes in first-degree relative compared to
controls (NDC = 11.7%, DNR = 28.4%%, DR = 24.4%, P
value: NDC vs DNR = 0.00011; NDC vs DR = 0.00023).
Frequency distribution and association of SLMAP gene
polymorphisms with T2DM with or without retinopathy
Assessment of the MAF of selected SLMAP gene poly-
morphisms in different ethnic groups/populations (based
on Hapmap data; http://hapmap.ncbi.nlm.nih.gov) dem-
onstrated that the frequencies of the selected SNPs were
heterogeneous among different populations, but there was
no data from the Qatari population (Additional file 1:
Table S1). The present study comprised 109 NDCs, ap-
proximately 50% of whom were metabolically healthy
obese (MHO). When we stratified NDC according to their
BMI (<30 vs >30) we did not observe any significant as-
sociation with SLMAP gene polymorphisms (data not
shown). Chi square test showed genotypic distributionjects (N = 342)
ents
160)
P value T2DM patients
with DR (N = 78)
P value P value
NDC vs DNR NDC vs DR DNR vs DR
3 4.702 ×10−10 57.86 ± 8.67 1.403 ×10−11 0.101
0.3252 36 (46.2%) 0.6073 >0.05
42 (53.8%)
2.5×10−8 9.92 ± 4.23 1.2 × 10−12 0.491
5.3 × 10−5 33.92 ± 6.53 0.001 0.867
5 0.529 81.5 ± 45.27 0.236 0.025
67) 5.2 × 10−9 8.82 ± 1.83 (73) 4.39 × 10−10 0.032
0.253 4.62 ± 1.08 0.022 0.105
0.003 1.21 ± 0.34 0.008 0.930
0.299 2.68 ± 1.04 0.021 0.085
0.457 0.55 ± 0.33 0.186 0.015
0.006 1.62 ± 0.75 0.005 0.394




%) 1.86 × 10−6 19/78 (24.4%) 0.0002 0.641
NA 63 (80.8%) NA 0.457
NA 56 (71.8%) NA 9.36 × 10−6
NA 23 (29.5%) NA 0.248
/102 0.00011 22 (52.4%)/42 0.00023 0.714
02 NA 14 (33.3%)/42 NA 0.546
retinopathy; DR = Diabetic retinopathy; NPDR = Non-proliferative diabetic
inopathy; DME = Diabetic macular edema; NA = not applicable; significant
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rs1057719 A > G polymorphisms were in agreement
with Hardy-Weinberg equilibrium in controls (PHWE >
0.05). There was no significant difference in distribution
of SLMAP rs17058639 C > T genotypes among T2DM
patients and NDCs. However, frequency of the CC
genotype was significantly higher in DR compared to
DNR (53.8% vs 37.5%, Table 2). When Binary logistic
regression was applied, SLMAP rs17058639 C > T poly-
morphism was not associated with risk of T2DM but
SLMAP rs17058639 CC genotype significantly conferred
enhanced risk of retinopathy in T2DM patients in ho-
mozygote and recessive models (CC vs TT: OR = 3.23,
95% CI = 1.22-8.52. P = 0.018; CC vs CT +TT: OR = 1.76,
95% CI = 1.15-2.68, P = 0.009). In allele contrast model,
SLMAP 1705863 C allele was also significantly associated
with higher risk of retinopathy in T2DM patients (OR =
1.76, 95% CI = 1.15-2.68, P = 0.009). For the other two
SLMAP gene polymorphisms (rs1043045 C > T and
rs1057719 A >G) there was no association with T2DM
alone or with DR (Table 2).
Stratification of subjects based on their gender indicated
that SLMAP rs17058639 C > T polymorphism might in-








(DNR) (N = 160)
O
C
SLMAP (rs17058639)C > T N (%) N (%)
TT 11 (10.6%) 29 (18.1%) R
CT 49 (47.1%) 71 (44.4%) 0
CC 44 (42.3%) 60 (37.5%) 0
TT + CT 60 (57.7%) 100 (62.5%) R
CC 44 (42.3%) 60 (37.5%) 0
T 71 (34.1%) 129 (40.3%) R
C 137 (65.9%) 191 (59.7%) 0
SLMAP (rs1043045)C > T
CC 11 (10.6%) 31 (19.4%) R
CT 51 (49.0%) 70 (43.8%) 0
TT 42 (40.4%) 59 (36.9%) 0
C 73 (35.1%) 132 (41.3%) R
T 135 (64.9%) 188 (58.8%) 0
SLMAP (rs1057719)A > G
GG 11 (10.6%) 30 (18.8%) R
AG 50 (48.1%) 71 (44.4%) 0
AA 43 (41.3%) 59 (36.9%) 0
G 72 (34.6%) 131 (40.9%) R
A 136 (65.4%) 189 (59.1%) 0
NDC = Non diabetic controls; T2DM = Type 2 Diabetes mellitus; DNR = Diabetic non-
and p-value; significant values shown in bold.recessive and allele contrast models (CC vs CT + TT:
OR = CI = 2.45, 95% CI = 1.03-5.84, P = 0.042; C allele
vs T allele: OR = 2.16, 95% CI = 1.09-4.27, P = 0.028);
however, upon applying Bonferroni correction for mul-
tiple comparisons P value did not reach the threshold
of significance (Additional file 1: Table S2). There was
no gender specific association of SLMAP rs1043045
and rs1057719 polymorphisms in DNR or DR groups
(Additional file 1: Table S2).
Association of SLMAP rs17058639 polymorphisms with
clinical phenotypes and progression of DR
Since only SLMAP rs17058639 polymorphism was asso-
ciated with the risk of DR, we also analyzed its inter-
action with various clinical parameters through one-way
ANOVA analysis. The SLMAP rs17058639 polymorph-
ism did not affect any of the clinical characteristics sug-
gesting it as an independent risk predictor (Additional
file 1: Table S3). The association of SLMAP rs17058639
polymorphism was also evaluated with prognosis of DR
by comparing its frequency with different severity levels
of DR. We performed “trend analysis” and found a signifi-
cant trend of association between SLMAP rs17058639 CC
genotype and diabetic macular edema (DME) suggesting ae polymorphisms with T2DM/DR
R* (95% CI) P T2DM patients
with DR (N = 78)
OR* (95% CI)P
ontrols vs T2DM DNR vs DR
N (%)
eference 6 (7.7%) Reference
.60 (0.26-1.39) 0.231 30 (38.5%) 2.08 (0.77-5.60) 0.146
.52 (0.22-1.22) 0.136 42 (53.8%) 3.23 (1.22-8.52) 0.018
eference 36 (46.2%) Reference
.77 (0.45-1.34) 0.357 42 (53.8%) 1.82 (1.04-3.18) 0.035
eference 42 (26.9%) Reference
.75 (0.51-1.12) 0.160 114 (73.1%) 1.76 (1.15-2.68) 0.009
eference 9 (11.5%) Reference
.56 (0.24-1.28)0.167 31 (39.7%) 1.57 (0.66-3.73) 0.306
.51 (0.22-1.19) 0.120 38 (48.7%) 2.09 (0.89-4.92) 0.090
eference 49 (31.4%) Reference
.76 (0.51-1.12) 0.162 107 (68.6%) 1.46 (0.97-2.20)0.068
eference 8 (10.3%) Reference
.59 (0.22-1.20) 0.215 32 (41.0%) 1.73 (0.71-4.23) 0.226
.51 (0.22-1.20) 0.125 38 (48.7%) 2.28 (0.94-5.53) 0.070
eference 48 (30.8%) Reference
.75 (0.50-1.11) 0.150 108 (69.2%) 1.49 (0.99-2.24) 0.058
retinopathy; DR = Diabetic retinopathy; *Age and gender adjusted odds ratio
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(Additional file 1: Table S4). There was a non-significant
trend for proliferative diabetic retinopathy (PDR).
Haplotype construction and their association with risk of
T2DM with or without retinopathy
Figure 1 shows haplotype organisation of the SLMAP
gene in the “CEU + TSI” population which was con-
structed using the Haploview v4.1 software using data
from the HapMap project. Haploblocks were defined by
four gamete rule and the r2 value among selected
SLMAP SNPs was >0.80 (rs17058639:rs1057719 = 0.98;
rs17058639: rs1043045 = 0.97; rs1057719: rs1043045 =
0.98). Haplotype analysis in present study (Qatari popula-
tion) also showed that all three selected SLMAP polymor-
phisms were in complete LD with each other in controls
(│D'│ = 1, P value = 0.0001; r2= >0.80) (Additional file 1:
Table S5; Figure 1). Four haplotypes were constructed.
Haplotype combination C rs17058639T rs1043045A rs1057719
(CTA) and Crs17058639C rs1043045G rs1057719 (CCG) were
associated with increased risk of retinopathy in T2DM
patients compared to haplotype T rs17058639C rs1043045G
rs1057719 (TCG) (OR = 1.79, 95% CI = 1.17-2.74, P value =
0.007; OR = 11.01, 95% CI = 2.20-55.11, P value = 0.005;
respectively). Also, when risk haplotypes were combined
together, haplotype combination CTA +CCG+CCA con-
ferred a two-fold increased risk of retinopathy in T2DM
in comparison with TCG haplotype (OR = 1.90, 95% CI =
1.25-2.90, P value = 0.003) (Table 3).
Multiple regression analysis for detecting cumulative DR
susceptibility predictors in the study
Since multiple clinical parameters and SLMAP
rs17058639 C > T polymorphisms were identified as in-
dependent risk factors for DR susceptibility among
T2DM patients, we checked for a holistic effect of se-
lected SLMAP gene polymorphisms and clinical pa-
rameters on risk of DR. Multiple regression analysis
showed SLMAP rs17058639 C > T gene polymorphismTable 3 SLMAP haplotype frequency and association with the




N (%) N (%)
T rs17058639C rs1043045G rs1057719 71 (34.14) 129 (40.31)
C rs17058639T rs1043045A rs1057719 135 (64.90) 188 (58.75)
C rs17058639C rs1043045G rs1057719 1 (0.48) 2 (0.63)
C rs17058639C rs1043045A rs1057719 1 (0.48) 0
Grouped analysis
T rs17058639C rs1043045G rs1057719 71 (34.1) 129 (40.4)
CTA + CCG + CCA 137 (65.9) 190 (59.6)
NDC = Non diabetic controls; T2DM = Type 2 Diabetes mellitus; DNR = Diabetic non-
adjusted odds ratio and p-value; significant values shown in bold.together with HbA1c and LDL were significant modu-
lators of DR in T2DM patients (Table 4).
Discussion
Overexpression of SLMAP correlates with endothelial
dysfunction in the microvasculature of diabetic db/db
mice [18], and several other studies have suggested the
role of SLMAP in diabetes and other macro/micro
vascular diseases [30-32]. In the present study we have
explored the genetic association of SLMAP gene poly-
morphisms [SLMAP rs17058639 C > T, rs1043045 C >
T and rs1057719 A > G] in the Qatari population,
which has one of the highest incidence of diabetes
worldwide. We have observed for the first time that
SLMAP rs17058639 C > T polymorphism is associated
with risk of DR among T2DM patients in the Qatari
population.
SLMAP genetic polymorphisms have heterogeneity in
their frequency distribution among different ethnic
groups. Upon comparing Hapmap data with present
study; MAF of SLMAP gene polymorphisms in Qatari
population was comparable with Mexican (MEX, M)
population (Additional file 1: Table S1) which is also a
high risk population for DR. Haffner et al. have showed
significant two fold higher risk of proliferative DR in
Mexican Americans compared to non-Hispanic whites
after adjusting all other significantly different predictors
[33]. These links suggest a possible similar SLMAP gen-
etic association with DR in Mexican population; how-
ever future multi-ethnic studies will be needed to come
at any conclusion.
Approximately fifty percent of NDCs in the present
study were obese, but we did not find any difference be-
tween genotype frequencies of SLMAP gene polymor-
phisms and BMI. We did not observe any significant
association of SLMAP gene polymorphisms between
T2DM without or with DR and NDC. However, SLMAP
rs17058639 C > T polymorphism was significantly asso-
ciated with DR in comparison to T2DM without DR.risk of DR development in T2DM patients
out OR* (95%CI) P T2DM patients
with DR (N= 156)
OR8* (95% CI) P
Controls vs T2DM N (%) DNR vs DR
Reference 41 (26.28) Reference
0.77 (0.53-1.10) 0.153 107 (68.59) 1.79 (1.17-2.74) 0.007
1.10 (0.10-12.35) 0.938 7 (4.49) 11.01 (2.20-55.11) 0.004
ND 1 (0.64) ND
Reference 41 (26.3) Reference
0.76 (0.53-1.10) 115 (73.7) 1.90 (1.25-2.90) 0.003
retinopathy; DR = Diabetic retinopathy; ND = not determined; *Age and gender
Table 4 Prediction of variable in study for the risk of developing DR in T2DM patients by multiple regression analysis







N (%) N (%)
Age (mean ± SD) 55.64 ± 10.23 57.86 ± 8.67 0.29 0.776
Gender (Males vs Females) 58 (36.3%)/102 (63.8%) 36 (46.2%)/42 (53.8%) 1.13 0.262
BMI (mean ± SD) 34.08 ± 6.99 33.92 ± 6.53 −0.463 0.644
Creatinine level (micromole/lit) ± SD 69.30 ± 28.55 81.5 ± 45.27 1.82 0.070
Glycated hemoglobin (HbA1c) mean% ± SD 8.24 ± 1.72 8.82 ± 1.83 1.99 0.048
LDL(mmol/lit)mean ± SD 2.95 ± 0.94 2.68 ± 1.04 −2.22 0.028
Triglycerides (mmol/lit) mean ± SD 1.77 ± 1.23 1.62 ± 0.75 −1.07 0.286
Blood Urea Nitrogen (mmol/lit) mean ± SD 5.24 ± 2.54 6.97 ± 4.49 −0.944 0.347
Mean Glucose levels (mmole/lit) ± SD 10.55 ± 6.68 9.92 ± 4.23 −0.165 0.87
SLMAP rs17058639 C > T genotypes TT = 29 (18.1%) TT = 6 (7.7%) −2.15 0.033
CT = 71 (44.4%) CT = 30 (38.5%)
CC = 60 (37.5%) CC = 42 (53.8%)
SLMAP rs1043045 C > T CC = 31 (19.4%) CC = 9 (11.5%) 0.95 0.294
CT = 70 (43.8%) CT = 31 (39.7%)
TT = 59 (36.9%) TT = 38 (48.7%)
SLMAP rs1057719 A > G GG = 30 (18.8%) GG = 8 (10.3%) 0.10 0.319
AG = 71 (44.4%) AG = 32 (41.0%)
AA = 59 (36.9%) AA = 38 (48.7%)
t= > +2 or < −2 depicts significance in data; significant values shown in bold.
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polymorphism may contribute to the risk of DR but not
to the susceptibility for T2DM.
Genetic variations may act as protective or risk factors;
but no definitive genetic associations with DR have been
consistently reported in the literature [34]. Candidate
gene analysis and systematic genome wide association
studies (GWAS) have identified a number of potential
susceptibility genes for DR e.g.: NOS2A, Bgl II, PAI-1,
APOE, MTHFR, SUV39H2, IGF-1, PEDF, ICAM-1 and
TCF7L2 [10,35,36]. The three candidate genes that have
been extensively studied and further analyzed by associ-
ation studies for their possible influence on DR are vas-
cular endothelial growth factor (VEGF), aldose reductase
(ALR), and the receptor for advanced glycation end
products (RAGE) [10,37].
We found that SLMAP rs17058639 C > T gene poly-
morphism might be associated with increased risk of DR
in male subjects but in the present study the association
did not reach statistical significance. The literature indi-
cates that the risk for T2DM was female gender biased
50 years ago but now due to the increase in sedentary
life style in men the risk of T2DM has shifted towards
male gender [38]. In Iran, the risk of DR has been re-
ported to be almost the same for both genders [39].
Since many known clinical risk factors for DRdevelopment were significantly elevated in the present
study we therefore have evaluate if any of these parame-
ters have an association with SLMAP rs17058639 C > T.
One-way ANOVA analysis revealed that SLMAP
rs17058639 C > T genotypes do not influence any of the
clinical parameters significantly, suggesting that SLMAP
(rs17058639) C > T polymorphism may be an independ-
ent predictor of DR. Multiple logistic regression analysis
showed that HbA1c%, LDL levels and SLMAP
(rs17058639) C > T gene polymorphisms were the main
predictors for DR risk among T2DM patients. This gen-
etic polymorphism was also found to be associated with
the trend of DR progression; but due to smaller sample
sizes in the sub grouped cells P values were either mar-
ginally significant or statistically non-significant.
The mechanistic reason for the significant association
of SLMAP rs17058639 C > T polymorphism with DR is
unknown but the SLMAP rs17058639 C > T polymorph-
ism (Exon 16 synonymous Asp447Asp) is presented at a
site for exonic splicing enhancer (ESE), a DNA sequence
motif consisting of 6 bases within an exon that directs
or enhances accurate splicing of hetero-nuclear RNA
(hnRNA) or pre-mRNA into messenger RNA (mRNA).
ESE is clinically significant because synonymous point
mutations previously thought to be silent mutations lo-
cated in an ESE can lead to exon skipping and
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ancestral and has an active site for ESE but its sub-
stitution by the T allele due to SNP (rs17058639) may
lead to production of non-functional or downregu-
lated SLMAP protein which may further reduce the
risk of T2DM or associated complications since the
SLMAP expression has been shown to be elevated in
microvascular diseases [18].
We did not observe any significant association with
the other two 3′ UTR region SLMAP gene polymor-
phisms selected in this study; however, the difference in
the allelic frequency among NDC, DNR and DR was ob-
vious. SLMAP rs1043045 C > T and SLMAP rs1057719
A > G polymorphisms have potential predicted func-
tional role in SLMAP expression. SNP function predic-
tion by SNPinfo has showed that SLMAP rs1043045 C
allele and SLMAP rs1057719 G alleles have binding sites
for hsa-miR-936 and hsa-miR-197 respectively, but the
substitution with polymorphic allele disrupts the bind-
ing of miRs. Allele specific binding of miRs reduce the
expression of SLMAP therefore SLMAP rs1043045 C
and SLMAP rs1057719 G alleles may function as
protective alleles in diabetic subjects. To detect any
synergistic effect of these two 3′ UTR region SNPs
with codonic SNP (rs17058639) for DR risk, haplotypes
were constructed and linkage disequilibrium was esti-
mated. All three SNPs were in complete linkage in con-
trols and haplotypes Crs17058639Trs1043045Ars1057719 and
Crs17058639Crs1043045Grs1057719 were found significantly
associated with DR risk in T2DM patients. This finding
conferred that SLMAP 3`UTR SNPs selected in this
study independently have no significant effect, but in
combination with SLMAP rs17058639 C > T poly-
morphism these may increase the susceptibility of DR
among T2DM patients.
The limitation of the present study is the small sample
size, especially in the subgroups; therefore the findings
should be interpreted cautiously and need to be con-
sidered as exploratory. Nonetheless, the novel findings
presented here provide the basis for future similar and
replicative studies in larger cohorts.
Conclusions
In conclusion, this exploratory study in the unique
high-risk population for T2DM (Qatari population) in-
dicates novel association of SLMAP gene polymor-
phisms with DR risk among T2DM patients. SLMAP
SNP rs17058639 C > T emerged as an independent risk
factor for DR risk; however, SLMAP rs1043045 C > T
and SLMAP rs1057719 A > G polymorphisms synergis-
tically contributed to the increased risk of DR among
T2DM patients. Therefore, SLMAP gene polymor-
phisms may be novel genetic predictors for the risk of
DR in the Qatari diabetic population.Additional file
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